The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease

Abstract

This study tested the hypothesis that avasimibe, an inhibitor of acyl coenzyme A-cholesterol acyltransferase (ACAT), would improve treadmill exercise performance in patients with claudication secondary to peripheral arterial disease (PAD). Four hundred and forty-two patients with PAD (ankle brachial index in the index leg of≤0.90 with a ≥20% reduction post-exercise) were enrolled from 39 centers in the USA. Patients were randomized to receive oral avasimibe 50 mg, 250 mg, 750 mg or placebo for a treatment period of 12 months. Changes from baseline in peak walking time (PWT) using a graded treadmill protocol were compared among groups after 6 and 12 months of treatment. Individual group comparisons were considered statistically significant if p< 0.0245 for the 50 mg and 250 mg groups and p< 0.001 for the 750 mg group. Patients randomized to the 50 mg group experienced a 0.76 min net increase over placebo in PWT, but this did not reach the pre-specified level of statistical significance (Hochberg procedure p=0.027) using ANCOVA after 12 months of treatment after adjusting for multiple comparisons. This trend in PWT was supported by the changes in treadmill initial claudication time (ICT) (p=0.026) and Walking Impairment Questionnaire (WIQ) walking distance score (p=0.058). The 250 mg and 750 mg avasimibe dose groups failed to demonstrate an improvement in PWT over placebo after 6 months of treatment. In conclusion, while the ACAT inhibitor avasimibe did not show clear evidence of benefit on treadmill exercise performance in patients with PAD, the results add to our knowledge of the impact of treatments directed at atherosclerosis on functional endpoints.

Keywords

atherosclerosis cholesterol clinical trials exercise performance intermittent claudication peripheral arterial disease

References

Golomb BA , Criqui MH , Bundens WP. Epidemiology. In: Creager MA (ed). Management of peripheral arterial disease. Medical, surgical, and interventional aspects. London: Remedica Publishing Limited, 2000: 1-18.

Criqui MH , Denenberg JO. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronaryarterydisease. Vasc Med 1998; 3: 241-245.

Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-1621.

CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.

Heinonen TM. Inhibition of acyl coenzyme A-cholesterol acyltranferase: a possible treatment of atherosclerosis? Curr Atheroscler Rep 2002; 4: 65-70.

Cases S , Novak S , Yao-Wu Z et al. ACAT-2, a second mammalian acyl-CoA: cholesterol acyltransferase. J Biol Chem 1998; 273:26755-26764.

Burnett JR , Wilcox LJ , Huff MW. Acyl-coenzyme A: cholesterol acyltransferase and hepatic apolipoprotein B secretion. Clin Chim Acta 1999; 286:231-242.

Kinnunen PM , DeMichele A , Lange LG. Chemical modification of acyl-CoA: cholesterol O-acyltransferase. 1. Identification of acyl-CoA: O-cholesterol O-acyltransferase subtypes by differential diethyl pyrocarbonate sensitivity. Biochemistry 1988; 27: 7344-7350.

Delsing DJM , Offerman EH , van der Boom H et al. The acyl-CoA: cholesterol acyltransferase (ACAT)-inhibitor avasimibe reduces atherosclerosis independently of its lipid-lowering effect in cholesterol-fed apoE3-Leiden transgenic mice. Circulation 1999; 100: I613-I613 (abstract).

10.

Bocan TMA , Krause BR , Rosebury WS et al. The ACAT inhibitor, avasimibe, reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 2000; 20:70-79.

11.

Niclosi RJ , Wilson TA , Krause BR. The ACAT inhibitor, CI-1011, is effective in prevention and regression of aortic fatty streak area in hamsters. Atherosclerosis 1998; 137:77-85.

12.

Vora J , Stern R , Lathia C. Clinical pharmacokinetics of CI-1011 an ACAT inhibitor. Pharm Res 1997; 14: S505-S505.

13.

Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-3023.

14.

Regensteiner JG , Steiner JF , Panzer RJ , Hiatt WR. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. J Vasc Med Biol 1990; 2:142-152.

15.

Myers GL , Cooper GR , Winn CL , Smith SJ. The Centers for Disease Control National Heart, Lung, and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. Clin Lab Med 1989; 9: 105-135.

16.

Steiner PM , Freidel J , Breminer WF , Stein E. Standardization of micro-methods for plasma cholesterol, triglyceride and HDL-cholesterol with the lipid clinic’s methodology. J Clin Chem Clin Biochem 1981; 19: 850-850 (abstract).

17.

Steel BW , Koehler DF , Azar MM , Blaszkowski TP , Kuba K , Demsey ME. Enzymatic determinations of cholesterol from high-densitylipoprotein fractions were prepared by a precipitation technique. Clin Chem 1976; 22:98-101.

18.

Albers JJ , Marcovina SM. Apolipoprotein measurements. In: Kreisber RA , Segrest JA (eds). Plasma lipoproteins and coronary artery disease. Boston: Blackwell Scientific Publications, 1992: 265-288.

19.

Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800-802.

20.

Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-1621.

21.

Labs K-H , Dormandy JA , Jaeger KA , Stuerzebecher C-S , Hiatt WR. Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease: clinical trial methodology. Basel PAD Clinical Trial Methodology Group. Circulation 1999; 100:e75-e81.